

medical archives



YEAR 2016 • VOLUME 70 • ISSUE 6

p ISSN 0350-199 X
e ISSN 1986-5961



C O P E

Select Issue



SUBMIT ARTICLE

MEDICAL ARCHIVES

Journal of the Academy of Medical Sciences of Bosnia and Herzegovina


Editorial Board



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

Ok


ORCID ID



IZET HOZO, MD, PhD

Co-Editor-In-Chief


ORCID ID



JACOB BERGSLAND, MD, PhD

Research Integrity Editor

ORCID ID



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.


[Ok](#)

Research Integrity Editor
ORCID ID



KENAN ARNAUTOVIC, MD PhD

Research Integrity Editor
ORCID ID



SLOBODAN JANKOVIC, MD PhD

Statistical Editor
ORCID ID


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

[Ok](#)



MIRZA HAMZIC, MA

Secretary



DUBRAVKO VANICEK, MA

Language Editor

Members of the Editorial Board

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

[Ok](#)

Prof. Benjamin Djulbegovic, MD, PhD (Department of Internal Medicine, University of South Florida (USF), Tampa, Florida, USA)

Prof. Vjekoslav Gerc, MD, PhD (Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina)

Prof. Mirko Grujic, MD, PhD (Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina)

Prof. Srecko Gajovic, MD, PhD (University of Zagreb School of Medicine, Croatian Institute for Brain Research, Zagreb, Croatia)

Prof. Jasenko Karamelic, MD, PhD (Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina)

Prof. Abdulah Kucukalic, MD, PhD (Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina)

Prof. Asim Kurjak, MD, PhD (Dubrovnik International University, Dubrovnik, Croatia),

Prof. Osman Sinanovic, MD, PhD (Faculty of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina),

Prof. Enver Zerem, MD, PhD (Faculty of Medicine, University of Mostar, Mostar, Bosnia and Herzegovina),

Prof. Sukrija Zvizdic, MD, PhD (Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina)

Prof. Emir Mujanovic MD, PhD (Heart Center Tuzla, Tuzla, Bosnia and Herzegovina)

Prof. Jasmin Caluk MD, PhD (Private Center "Kardiocentar", Sarajevo, Bosnia and Herzegovina)

Prof. Miro Jakovljevic MD, PhD (School of Medicine, Zagreb, Croatia)

Prof. Milivoje Boranic MD, PhD (School of Medicine, Zagreb, Croatia)

Prof. Snjezana Milicevic MD, PhD (Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina)

Prof. Ahmad-Reza Jamshidi, MD, PhD (Rheumatology Research Center Tehran University of Medical Sciences, Tehran, Iran)

Prof. Dzelaludin Junuzovic MD, PhD (Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina)

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

Ok



ADDRESS:

Sarajevo, Mis Irbina 11, Fax +387 33 226-866, E-mail: amnubih@gmail.com, www.amn.ba

PUBLISHER:

Academy of Medical Sciences of Bosnia and Herzegovina, Mis Irbina 11, 71000 Sarajevo, Phone: + 387 33 226 866, Fax: + 387 33 226 866, Mob: + 387 61 898 636, E-mail: amnubih@gmail.com, www.amn.ba

Journal "Medical Archives" s published six times per year (Feb, Apr, Jun, Aug, Oct, Dec).

The journal is abstracted and indexed by PubMed, PubMed Central, Europe PubMed Central, Scopus, EMBASE, Scirus, EBSCO, Index Copernicus, Ulrich's Periodicals Directory, Geneva Foundation for Medical Education and Research – GFMER, HINARI, CAB Abstracts, Global Health, ProQuest, NewJour, SCImago Journal and Country Rank, ISC Master Journals List, CrossRef, Google Scholar, Genamics JournalSeek, WorldCat, VINITI of RAS, Research Gate, Catalyst, ScopeMed, SafetyLit, BioinfoBank Library, PubGet, GetCited, CIRRIE, Kubon and Sagner OPAC

MEDICAL ARCHIVES

Journal of the Academy of Medical Sciences of Bosnia and Herzegovina

COPE

 ICMJE



Medical Archives is official journal of Academy of Medical Sciences
in Bosnia and Herzegovina

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

Ok



C O P E

Select Issue

SUBMIT ARTICLE

MEDICAL ARCHIVES

Journal of the Academy of Medical Sciences of Bosnia and Herzegovina

Issue: 74-2

Amnioreduction in Emergency Rescue Cervical Cerclage with Bulging Membranes

Edin Medjedovic, Zijo Begic, Alma Suljevic, Amela Muftic, Ema Dzihic, Asim Kurjak

MEDARCH:2020; 74-2: 151-152

[PDF - FULL TEXT](#) | DOI: 10.5455/medarh.2020.74.151-152

Uncontrolled Acute Intermittent Porphyria as a Cause of Spontaneous Abortion

Anis Cerovac, Alma Brigic, Dzenana Softic, Amna Barakovic, Semir Adzajlic

MEDARCH:2020; 74-2: 153-155

[PDF - FULL TEXT](#) | DOI: 10.5455/medarh.2020.74.153-155

The Effect of Aerobic Physical Activity in Adrenaline Level in White Laboratory Rats

Arbnore Ibrahimaj Gashi, Seryozha Gontarev, Vujica Zivkovic, Icko Gjorgovski, Arjeta Azemi

MEDARCH:2020; 74-2: 84-89

[PDF - FULL TEXT](#) | DOI: 10.5455/medarh.2020.74.84-89

Thalassemia Major and Intermedia Patients in East Java do not Show Fetal Hemoglobin Level Difference in Relation to XMNI Polymorphism

Retno Dwi Wulandari, Diana Lyrawati, Fatchiyah Fatchiyah, Loeki Enggar Fitri

MEDARCH:2020; 74-2: 90-94

[PDF - FULL TEXT](#) | DOI: 10.5455/medarh.2020.74.90-94

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

Ok

MEDARCH:2020; 74-2: 95-99

[PDF - FULL TEXT](#) | DOI: 10.5455/medarh.2020.74.95-99

Comparing the Efficacy of Radiofrequency Ablation Versus Laser Ablation for Chronic Venous Insufficiency in the Lower Extremities: a Vietnamese Report

Tran Anh Tuan, Nguyen Minh Duc, Le Nguyet Minh, Hoang Duc Ha, Vu Dang Luu, Pham Minh Thong

MEDARCH:2020; 74-2: 100-104

[PDF - FULL TEXT](#) | DOI: 10.5455/medarh.2020.74.100-104

Pachymetry and Elevation Back Map Changes in Keratoconus Patients After Crosslinking Procedure

Melisa Ahmedbegovic Pjano, Alma Biscevic, Senad Grisevic, Ivan Gabric, Ajla Skopljak Salkica, Nina Ziga

MEDARCH:2020; 74-2: 105-108

[PDF - FULL TEXT](#) | DOI: 10.5455/medarh.2020.74.105-108

Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience

Isidora Kacarska □ Fotevska, Nadja Volckova, Katerina Ilievska, Doncho Donev

MEDARCH:2020; 74-2: 109-114

[PDF - FULL TEXT](#) | DOI: 10.5455/medarh.2020.74.109-114

Urgent Surgical Treatment of Blunt Chest Trauma Followed by Cardiac and Pericardial Injuries

Dusan Janicic, Milan Simatovic, Zoran Roljic, Ljiljana Krupljanin, Reuf Karabeg

MEDARCH:2020; 74-2: 115-118

[PDF - FULL TEXT](#) | DOI: 10.5455/medarh.2020.74.115-118

New Functional Evaluation Scheme – Modality of the Results of Forearm Tendon Transfers Evaluation in Cases of Irreparable Radial Nerve Injury

Reuf Karabeg

MEDARCH:2020; 74-2: 119-125

[PDF - FULL TEXT](#) | DOI: 10.5455/medarh.2020.74.119-125

1 2 Next »

MEDICAL ARCHIVES

Journal of the Academy of Medical Sciences of Bosnia and Herzegovina

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

Ok

ORIGINAL PAPER

doi: 10.5455/medarch.2020.74.90-94

MED ARCH. 2020 APR; 74(2): 90-94

RECEIVED: JAN 12, 2020 | ACCEPTED: MAR 12, 2020

Thalassemia Major and Intermedia Patients in East Java do not Show Fetal Hemoglobin Level Difference in Relation to XMNI Polymorphism

Retno Dwi Wulandari^{1,2}, Diana Lyrawati³, Fatchiyah Fatchiyah⁴, Loeki Enggar Fitri⁵

ABSTRACT

Introduction: Thalassemia is a genetic disorder, which shows, varies phenotype due to genetic modifier. *Xmnl* is one of the genetic modifiers which affect clinical severity in thalassemia. *Xmnl* polymorphism may increase HbF production beyond fetal life, thus ameliorating the clinical phenotype. **Aim:** this study aimed to investigate the difference in HbF level and the relation of HbF level and *Xmnl* polymorphism in Thalassemia Major (TM) and Thalassemia Intermedia (TI) patients. **Methods:** forty-eight beta thalassemia patients (28 males and 20 females), consists of 16 TM and 32 TI; mean age, 25.30 year old. Hemoglobin Fetal and HbA₂ level were determined using High performance Liquid Chromatography (HPLC), and *Xmnl* polymorphism was confirmed by PCR-RFLP. Statistical analysis was done using T-test, Mann-Whitney and Pearson Chi-square. **Results:** The frequency of heterozygote (+/-) *Xmnl* polymorphism in TM and TI patients was 56.25% vs 71.87%, while the frequency of homozygote (-/-) in TM and TI was 43.75% vs 28.13% with p value >0.05. The insignificant difference also found in HbF level between *Xmnl* +/- and -/- in TM and TI patients. **Conclusion:** This study revealed that thalassemia major and thalassemia intermedia patients in East Java showed similar *Xmnl* polymorphism. These phenomena also showed by HbF level in relation to *Xmnl* polymorphism in the phenotype groups (TM and TI).

Keywords: thalassemia, major, intermedia, HbF level, *Xmnl*.

¹Doctoral Program in Medical Science, Faculty of Medicine, University of Brawijaya, Indonesia

²Department of Biomedical, Faculty of Medicine, University of Wijaya Kusuma Surabaya, Indonesia

³Department of Pharmacy, Faculty of Medicine, University of Brawijaya, Indonesia

⁴Department of Biology, Faculty of Mathematics and Natural Sciences, University of Brawijaya, Indonesia

⁵Department of Parasitology, Faculty of Medicine, University of Brawijaya, Indonesia

Corresponding author: Retno Dwi Wulandari, Dr. drg., M. Kes. Department of Biomedical, Faculty of Medicine, University of Wijaya Kusuma Surabaya, Jl. Dukuh Kupang XXV/54 Surabaya 60225, Indonesia. Tel +62-31-5670495. E-mail: retno_dwi_w@yahoo.com. ORCID ID <https://orcid.org/0000-0002-3381-177X>.

1. INTRODUCTION

Thalassemia is one of the common genetic diseases in the world that characterized by chronic hemolytic anemia. Thalassemia patients with severe condition that needs regular blood transfusion were categorized as thalassemia major (TM), while those with milder disease severity are considered as thalassemia intermedia (TI). Thalassemia intermedia patients usually need medical attention later in childhood, or adulthood and do not need regular transfusion to survive (1).

The clinical severity in thalassemia depends on three different mechanisms of genetic modifiers. The first modifiers represent the inheritance of beta globin mutation, which affect beta globin gene production, from slightly reduced to totally absent beta chain production (finally, these determine the degree of alpha/beta globin imbalance). The second modifiers are the co-inheritance of alpha gene mutation (which decreases the unbound alpha globin chain). Similarly, the imbalance in globin chain

production could be reduced by over expression of gamma globin gene that elevates HbF level in the adult. The third modifiers included those which affect the complication of the disease but not related with globin chain production (1).

In adult, the predominant gene is alpha and beta globin to form HbA ($\alpha_2\beta_2$) while in newborn baby. The 60-80% of total hemoglobin is HbF ($\alpha_2\gamma_2$). Although HbF was found abundant in fetal life, but before two years, its level decrease to less than 1% until adult life (2, 3). The switch occurs just before birth, when beta globin replaces fetal gamma globin, which involves the same alpha globin (4). The switch mediated by Locus Control Region (LCR) on beta globin gene. Physical bending of chromatin needed to bring the LCR promotor first to gamma globin gene before switched to the beta globin gene (4). In beta thalassemia, there is delayed switch from gamma globin to beta globin expression, and as consequently HbF levels remain above normal in most patients. Beta thalas-

© 2020 Retno Dwi Wulandari, Diana Lyrawati, Fatchiyah Fatchiyah, Loeki Enggar Fitri

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

semia patients usually clinically present after 2 year of age (5), following the decrease in HbF production as the switch occur (6).

XmnI polymorphism was one of the genetic modifier known, which can modified gamma chain production. The polymorphism result in highly expressed gamma globin gene leading to increasing HbF level in adult life (7). The elevated HbF production may compensate for the low HbA level which caused by the abnormal beta globin chain. The polymorphism site located in -158 promoter HBG2 gene will change C > T. Some studies reported significant association between the *XmnI* polymorphism and HbF level (8, 9). Carriers of the T allele of *XmnI* have shown to be more possible having a milder disease course (4). Research showed that the increasing of HbF production beyond fetal life has been a benefit for beta thalassemia patients as it can ameliorate the thalassemia phenotype (2) although negative relation also reported (10).

2. AIM

In this study we aimed a) to investigate the frequency of *XmnI* polymorphism in thalassemia major and intermedia; b) to investigate the HbF level difference according to gender and the *XmnI* polymorphism of phenotype group in both thalassemia major and intermedia; and c) to determine difference of HbF level in relation to *XmnI* polymorphism between thalassemia major and thalassemia intermedia patients in East Java, Indonesia.

3. MATERIAL AND METHODS

This research study approved by Ethical Committee of Health Research of Medical Faculty Wijaya Kusuma Surabaya University (No.10198/SLE/FK/UWKS/2018).

Patients

The thalassemia patients were member of Indonesian thalassemia's parents association (POPTI). Thalassemia major (TM) patients were those who started transfusion before 5 year old with the needs regular (6-12 times per year) transfusion. Thalassemia intermedia patients started transfusion at 5 years old and after, with transfusion rate 0-12 times per year.

Sample preparation

After signing an informed consent, 10 ml blood was obtained from peripheral blood and collected in vacutainer for hematologic analysis including High Performance Liquid Chromatography (HPLC) assays. Hematologic analysis was taken by using Advia 2120 Siemens. HPLC analysis was conducted using VariantTM II Thalassemia Short Program (Bio-Rad Laboratories, Hercules, CA, USA). The VARIANT II β -thalassemia Short Program utilizes principles of ion exchange high performance liquid chromatography (HPLC). The samples are automatically mixed and diluted on the VARIANT II Sampling Station (VSS) and injected to the analytical cartridge. The VARIANT II Chromatographic Station (VCS) dual pumps deliver a programmed buffer gradient of increasing ionic strength to the cartridge, where the HbA₂/F are separated based on their ionic interactions with the cartridge material. The separated HbA₂/F then

pass through the flow cell of the filter photometer, where changes in the absorbance at 415 nm are measured. An additional filter at 690 nm corrects the background absorbance. The VARIANT II Clinical Data Management (CDM) software performs reduction of raw data collected from each analysis. One-level calibration is used for adjustment of the calculated HbA₂/F values. A sample report and a chromatogram are generated by CDM for each sample.

We used a solvent reagentse.i. Elution buffer 1 and 2 (containing sodium phosphate buffer), Whole Blood Primer (containing lyophilized human red blood cell hemolysate with gentamicin, tobramycin and EDTA as preservatives), HbA₂/HbF calibrator/diluent set (lyophilized human red blood cell hemolysate containing gentamicin, tobramycin and EDTA as preservatives), and Diluent (contains deionized water with less than 0.05% sodium azide as a preservative).

Running method: HbA₂/HbF calibrator reconstituted with calibrator diluent. The Whole Blood Primer prepared by adding deionized water to the vial. Vials prepared for Variant whole blood primer, deionized water, Variant A₂/F calibrator, positive and negative control, stop tube and vials for samples/patients. Vial 1 contains primer, vial 2 contains deionized water, vial 3 and 4 contain HbA₂/HbF calibrator, vial 5 and 6 contain control level 1 and 2, vial 7 to N contain patient samples, N+1 and N+2 contain control level 1 and 2, N+3 is stop tube. The result will be printed out from the HPLC.

PCR analysis of *XmnI* polymorphism

The *XmnI* was identified using PCR with primer pair: Forward (5'-AACTGTTGCTTTATAGGATTTT-3') and Reverse (5'-AGGAGCTTATTGATAACTCAGAC-3') and PCR profile as described by Said & Abdel-Salam (2015) (2). PCR was performed using Veriti (Applied

Parameter	N(%)	Mean (±SD)	Range	p-value
Gender	48			
Male	28(58.33)	10.8(9.8)	2.7-45.8	0.184
Female	20(41.67)	8.8(8.9)	1.1-37.5	
<i>XmnI</i> polymorphism				
Heterozygote (+/-)	32(66.7)	11.86(10.88)	1.1-45.8	0.058
Homozygote (-/-)	16(33.3)	6.27(3.45)	2.7-15.5	

Table 1. Comparison of Mean HbF level (%) in Relation to Gender and *XmnI* polymorphism

Variable	All samples	TM (n=16)	TI (n=32)	p value
HbA ₂ level (%)				
Mean	31.28	25.93	33.95	0.225
Median	27.9			
Range	6.2 – 69.8			
HbF level (%)				
Mean	9.99			0.060
Median	7	6.48	11.76	
Range	2 – 45.8			

Table 2. The level comparison of HbA₂ and HbF on TM and TI

Phenotype	<i>XmnI</i> -/ (n=16)	<i>XmnI</i> +/- (n=32)	p value
TM (n=16)	7(43.75%)	9(56.25%)	0.279
TI (n=32)	9(28.13%)	23(71.87%)	

Table 3. The Frequency of *XmnI* -/- and *XmnI* +/- polymorphism in TM and TI

Phenotype	Level of HbF		P value
	<i>XmnI</i> -/ Mean (\pm SD)	<i>XmnI</i> +/- Mean (\pm SD)	
TM	5.71(3.44)	7.07(4.71)	0.536
TI	6.70(3.61)	13.73(12.07)	0.122
P value	0.470	0.157	

Table 4. The Level of HbF in homozygote (-/-) and heterozygote *XmnI* Polymorphism between TM and TI



Figure 1. Gel electrophoresis of G gamma gene (-158 C>T) PCR-RFLP with *XmnI* restriction enzyme. Lane 1 (left side): DNA marker 100 bp, lane 2: 650 bp band from patient with *XmnI* (-/-) polymorphism, lane 3-5: 650bp, 450 bp and 200 bp bands from patients with *XmnI* (+/-) polymorphism.

Biosystem, USA). The PCR product was then run in 2% gel electrophoresis.

If there was band, the process continued to digest the PCR product with restriction enzyme.

RFLP analysis of *XmnI* polymorphism

The PCR product was then digested using *XmnI* restriction enzyme (Biolabs) following its instruction, yielding +/+ genotype as indicated having 450 and 200bp, heterozygote genotype (+/-) showed 3 bands at 650, 450 and 200bp and -/- genotype showed only band at 650 bp after run in 2% agarose gel electrophoresis (Figure 1)

Statistical analysis

Data are presented as mean \pm SD, range and percentage. T-test was performed to analyze the difference of the mean, first transfusion age and transfusion rate per year between phenotype groups (TM and TI). Hemoglobin Fetal level difference according to sex and *XmnI* (-/- and +/- polymorphism) was analyzed using Mann-Whitney test. The Mann-Whitney test also used to analyze the difference of HPLC results (HbA₂ and HbF) between phenotype groups as well as the relation between HbF level and *XmnI* polymorphism in TM and TI. Pearson's Chi-squared was used to compare between *XmnI* -/- and *XmnI* +/- polymorphism in TM and TI. P value < 0.05 was considered statistical significant. Data were analyzed using SPSS 20.

4. RESULTS

A number of 48 patients which 28 (58.35%) were males and 20 (41.7%) were females involved in this study. Although the number of female patients in this study was lower than male, but since thalassemia inherited as autosomal recessive, means that female and male have the same chance to get the disease. The sample's age data (mean age 25.30 yo) with the difference of mean age between male (24.01yo) and female (27.1yo) was not significant (p=0.24). In this study, *XmnI* gene polymorphism was only found in heterozygote form with overall frequency was 66.7%. Mean HbF level comparison between heterozygote (+/-) *XmnI* polymorphism and homozygote (-/-) genotype showed nearly significant difference, while comparison between male and female showed no significant difference (Table 1).

After grouped into TM and TI, the mean age of TM was 21.75yo and TI 27.08yo (p value = 0.052); mean age of 1st transfusion was 2.59yo vs. 11.68yo (p value = 0.00), while mean transfusion rate/year 9.52 vs. 7.7 (p value = 0.169).

The comparison of HbA₂ and HbF level between TM and TI patients presented in Table 2 where the insignificant difference found in both mean HbA₂ and HbF level between TM and TI patients.

Among TM and TI patients, more patients showed heterozygote *XmnI* polymorphism than homozygote (-/-). The frequency of heterozygote *XmnI* polymorphism was 71.87% in TI group compared to 56.25% in TM group. The difference of *XmnI* polymorphism's frequency between TM and TI presented in Table 3, which showed that there was no significant difference between the homozygote (-/-) and heterozygote (+/-) *XmnI* polymorphism in TM and TI patients (p=0.279).

HbF level comparison between phenotype (TM and TI) and *XmnI* polymorphism are presented in Table 4.

The mean HbF level both in TM and TI patient with heterozygote *XmnI* polymorphism was higher compared to those with the absence of polymorphism, but the difference was not significant (p = 0.536 and p = 0.122); the mean HbF level difference between TM and TI with homozygote (-/-) and heterozygote *XmnI* polymorphism also did not showed significant difference (p = 0.470 and p = 0.157) respectively.

5. DISCUSSION

Thalassemia major patients refer to those who need regular transfusion which started before 2 year old, but occasionally the presentation could be delayed until 4-5 years (11, 12).

In this study, patients got transfusion before 5 year old, as there were possibilities delayed which may be due to factors such as: a) the lack of parents' knowledge or caring for their children; b) socioeconomic factor; c) the knowledge of health worker about the disease; d) the limitation of thalassemia prevention program in identifying thalassemia earlier. While to be survive, patients with thalassemia intermedia usually do not need regular transfusion, or only occasional and can be even more frequent in certain condition (13). We found that

some TI patients got 12 times per year although the first transfusion received later in age. The possibilities were: a) transfusion needed for growth and development; b) recurrent infection (patients with middle-low economic status); c) social purposes, if it needed for activity.

In the case of relation to activity needs, some mothers asked for transfusion before their child started to have exam. Taher, et al (2015) (14) reported that there was possibility that some HbE/ β thalassemia (TI) patients got unnecessary transfusion as severe anemia and acute haemolysis exacerbated by infection.

Beta thalassemia patients usually show increasing HbA₂ and HbF level. By examination using HPLC, hemoglobin variants such as HbS, HbE, and Hb Lepore result in higher HbA₂ levels compared to those using capillary electrophoresis (CE) due to co-elution (15). Our data showed that the level of HbA₂ in TI was higher than TM although the difference was not significant. Khera, et al (2015) (16) also reported that it might be caused by more HbE variant in TI than TM.

Although there is elevation of HbF production in beta thalassemia, this study showed that the mean HbF level was not different in relation to gender. This result in line with study by Lim, et al. (17). We also found that the overall positive heterozygote *XmnI* polymorphism frequency was quite high (66.7%), although there was no difference between homozygote (-/-) and heterozygote *XmnI* polymorphism in TM and TI. This result confirmed the earlier studies by Neishabury, et al (2010) and Said & Abdel-Salam (2015) which showed no relation between C to T substitution in *XmnI* polymorphism with phenotype severity (thalassemia major and intermedia) (2, 18).

Research showed that the increasing of HbF production beyond fetal life has been a benefit for beta thalassemia patients as it can ameliorate the thalassemia phenotype (2) by reducing the imbalance in alpha/beta globin chain synthesis. This would lead to a milder phenotype, thalassemia intermedia, despite similar beta genotype and no co-inheritance of alpha mutation (2, 5, 17). Although in this study HbF level in TI was higher than in TM but the difference was not significant. As presented in Table 3, the polymorphism was only found in heterozygote form, while among +/- *XmnI* polymorphism, the number of TI patients showed higher percentage compared to TM (p value >0.05). This was one of few studies, which found that *XmnI* polymorphism difference between TM and TI was not significant. This result in line with previous study by Tyagi, et al (2003) which resulted no statistically significant difference between positive heterozygote *XmnI* polymorphism in thalassemia major and thalassemia intermedia (10).

Interestingly, this study found a new frequency of heterozygote polymorphism. The frequency of heterozygote polymorphism in this study was different from previous study done on HbE/ β and β thal/ β thal patients in Central Java, Indonesia, which found +/+ polymorphism in 3.7% and +/- polymorphism in 20.6% samples (8). The difference from previous study may be due to difference frequency in the different population.

Patients with heterozygote *XmnI* polymorphism showed higher expression of HbF compared to those without polymorphism with nearly significant difference (p value = 0.058). The insignificant difference also showed when HbF level in homozygote *XmnI* (-/-) and heterozygote (+/-) polymorphism compared between phenotype group (TM and TI). This showed that HbF level and *XmnI* polymorphism could not make the significant difference between TM and less severe TI phenotype. The most possibility for main contributor was the inheritance of mild beta mutation in TI than *XmnI* polymorphism.

To our knowledge, this is the first study that reports the frequency of *XmnI* polymorphism and HbF level comparison in relation to *XmnI* polymorphism in Thalassemia Major and thalassemia intermedia in East Java, Indonesia.

6. CONCLUSION

This study demonstrates that thalassemia major and intermedia patients in East Java do not show homozygosity (+/+) of *XmnI* polymorphism, while the heterozygous state (+/-) shows the highest frequency. There is no *XmnI* (-/-) and (+/-) polymorphism difference between thalassemia major and thalassemia intermedia patients. The HbF level in relation to *XmnI* polymorphism between thalassemia major and intermedia patients do not show difference as well. It needs further research to determine the main contributor to the less severe phenotype in thalassemia intermedia patients.

Limitation of the study: According to small patient population, it limits us to draw general conclusion, that it may needs further study to prove the finding with larger sample size and different population for thalassemia major and thalassemia intermedia patients.

- **Acknowledgements:** Our appreciation to thalassemia patients (POP-TI members) for willingness to participate in this study.
- **Author's contribution:** Each author gave a substantial contribution to the conception and design of the work. RDW contributed to acquisition, analysis and interpretation of data as well as in drafting the article. RDW, DL, FF, & LEF had a role in critically revising the article for important intellectual content. Each author gave final approval of the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
- **Conflict of interest:** There was no conflict of interests.
- **Financial support and sponsorship:** This study was partly funded by grant from the Ministry of Research, Technology, and Higher Education of Indonesia.

REFERENCES

1. Musallam KM, Sankaran VG, Cappellini MD, Duca L, Nathan DG, Taher AT. Fetal hemoglobin levels and morbidity in untransfused patients with β -thalassemia intermedia. *Blood*. 2012; 119(2): 364-367.
2. Said F, Abdel-Salam A. *XmnI* polymorphism : Relation to β -thalassemia phenotype and genotype in Egyptian Children.

- Egypt J Med Hum Genet. 2015; 16: 123-127.
3. Mosca A, Paleari R, Leone D, Ivaldi G. The relevance of hemoglobin F measurement in the diagnosis of thalassemias and related hemoglobinopathies. *Clin Biochem*. 2009; 42(18): 1797-1801. Available from: <http://dx.doi.org/10.1016/j.clinbiochem.2009.06.023>
 4. Guha BG, Sharma SK. Raised Haemoglobin F (HbF) Level in Haemoglobinopathies : an Indicator of Polymorphism. *Int J Sci Res*. 2014; 3(7): 532-536.
 5. Sripichai O, Fucharoen S. Fetal hemoglobin regulation in β -thalassemia : heterogeneity, modifiers and therapeutic approaches. *Expert Rev Hematol*. 2016; 9(12): 1129-1137. Available from: <http://dx.doi.org/10.1080/17474086.2016.1255142>
 6. Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Clinical experience with fetal hemoglobin induction therapy in patients with β -thalassemia. *Blood*. 2013; 121(12): 2199-2212.
 7. Danjou F, Anni F, Perseu L, Satta S, Dessi C, Lai ME, et al. Genetic modifiers of β -thalassemia and clinical severity as assessed by age at first transfusion. *Haematologica*. 2012; 97(7): 989-993.
 8. Rujito L, Basalamah M, Siswandari W, Setyono J, Wulandari G, Mulatsih S, et al. Modifying effect of XmnI , BCL11A , and HBS1L-MYB on clinical appearances : A study on β -thalassemia and hemoglobin E / β -thalassemia patients in Indonesia. *Hematol Oncol Stem Cell Ther*. 2016; (1): 1-9. Available from: <http://dx.doi.org/10.1016/j.hemonc.2016.02.003>
 9. Dadheech S, Jain S, Madhulatha D, Sharma V, Joseph J, Jyothy A, et al. Association of XmnI -158 γ G variant with severity and HbF levels in β -thalassemia major and sickle. *Mol Biol Reports Vol*. 2014; 41: 3331-3337. doi:10.1007/s11033-014-3195-5.
 10. Tyagi S, Kabra M, Tandon N, Saxena R, Pati HP, Choudhry VP. Clinico-Haematological Profile of Thalassemia Intermedia Patients. *Int J Hum Genet*. 2003; 3(4): 251-258.
 11. Hassan T, Badr M, El Safy U, Hesham M, Sherief L, Zakaria M. β -Thalassemia: Genotypes and Phenotypes. In: *Epidemiology of Communicable and Non-Communicable Diseases - Attributes of Lifestyle and Nature on Humankind*. 2016: 113-126.
 12. Badens C, Joly P, Agouti I, Thuret I, Gonnet K, Fattoum S, et al. Variants in genetic modifiers of β -thalassemia can help to predict the major or intermedia type of the disease. *Haematologica*. 2011; 96(11): 1712-1714.
 13. Musallam K, Rivella S, Vinchinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. *Haematologica*. 2013; 98(6): 833-844.
 14. Taher AT, Radwan A, Viprakasit V. When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia. *Vox Sang*. 2015; 108(1): 1-10.
 15. Hafiza A, Malisa M, Khiretdin A, Azlin I, Azma R, Thong M, et al. HbA2 levels in normal β -thalassaemia and haemoglobin E carriers by capillary electrophoresis. *Malaysian J Pathol*. 2012; 34(2): 161-164.
 16. Khera R, Singh T, Khuana N, Gupta N, Dubey AP. HPLC in Characterization of Hemoglobin Profile in Thalassemia Syndromes and Hemoglobinopathies : A Clinicohematological Correlation. *Indian J Hematol Blood Transfus*. 2015; 31(1): 110-115.
 17. Lim WF, Muniandi L, George E, Sathar J, Teh LK, Lai MI. HbF in HbE: β -thalassemia: A clinical and laboratory correlation. *Hematology*. 2015; 20(6): 348-353.
 18. Neishabury M, Azarkeivan A, Najmabadi H. Frequency of Positive XmnI G γ polymorphism and coinheritance of common alpha thalassemia mutations do not show statistically significant difference between thalassemia major and intermedia cases with homozygous IVSII-1 mutation. *Blood Cells Mol Dis*. 2010; 44(2): 95-99.